Active Biotech

April 14, 2011 07:46 ET

Active Biotech's nomination committee proposes election of an additional new board member

LUND, SWEDEN--(Marketwire - Apr 14, 2011) - As previously announced, Active Biotech's nomination committee has proposed that the annual general meeting on 5 May 2011 re-elect Mats Arnhög, Klas Kärre, Magnhild Sandberg-Wollheim and Peter Sjöstrand as board members and that Peter Hofvenstam and Peter Thelin be elected new members of the board.

The nomination committee now expands its proposal and proposes that Mef Nilbert be elected new member of the board. Mef Nilbert, M.D., PhD, is 44 years old, chief physician at the oncology clinic at Skåne University Hospital and professor of oncology at Lund University. Mef Nilbert also holds a cancer research professorship at Copenhagen University. She has extensive experience within the field of cancer research. According to the nomination committee, Mef Nilbert would contribute further valuable expertise within cancer research.

For further information, please refer to the nomination committee's revised proposal to the annual general meeting, which is available at Active Biotech's webpage,

Lund, April 14, 2011

Active Biotech AB (publ)

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as RhuDex™ for RA. Please visit for more information.

Active Biotech is required under the Swedish Securities Market Act to make the information in this press release public. The information was submitted for publication at 1.30 p.m. CET on April 14, 2011.

Active Biotech?s nomination committee proposes election:

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that:

(i) the releases contained herein are protected by copyright and other applicable laws; and

(ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE


Contact Information

  • Active Biotech AB
    (Corp. Reg. No. 556223-9227)
    Box 724, SE-220 07 Lund
    Tel: +46 46 19 20 00
    Fax: +46 46 19 11 00